214 related articles for article (PubMed ID: 18516323)
1. Prostate-specific antigen may serve as a pathological predictor in breast cancer.
Nariţa D; Anghel A; Motoc M
Rom J Morphol Embryol; 2008; 49(2):173-80. PubMed ID: 18516323
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen value as a marker in breast cancer.
Narita D; Cimpean AM; Anghel A; Raica M
Neoplasma; 2006; 53(2):161-7. PubMed ID: 16575473
[TBL] [Abstract][Full Text] [Related]
3. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
[TBL] [Abstract][Full Text] [Related]
4. Do we need HER-2/neu testing for all patients with primary breast carcinoma?
Taucher S; Rudas M; Mader RM; Gnant M; Dubsky P; Bachleitner T; Roka S; Fitzal F; Kandioler D; Sporn E; Friedl J; Mittlböck M; Jakesz R
Cancer; 2003 Dec; 98(12):2547-53. PubMed ID: 14669272
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical identification of basal-type cytokeratins in invasive ductal breast carcinoma--relation with grade, stage, estrogen receptor and HER2.
Kusińska R; Potemski P; Jesionek-Kupnicka D; Kordek R
Pol J Pathol; 2005; 56(3):107-10. PubMed ID: 16334976
[TBL] [Abstract][Full Text] [Related]
6. Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan.
Sharif MA; Mamoon N; Mushtaq S; Khadim MT
J Coll Physicians Surg Pak; 2009 Feb; 19(2):99-103. PubMed ID: 19208313
[TBL] [Abstract][Full Text] [Related]
7. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
8. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
[TBL] [Abstract][Full Text] [Related]
9. Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression.
Park SS; Kim SW
Oncol Rep; 2007 Jul; 18(1):139-43. PubMed ID: 17549359
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical expression of androgen receptor and prostate-specific antigen in breast cancer.
Narita D; Raica M; Suciu C; Cîmpean A; Anghel A
Folia Histochem Cytobiol; 2006; 44(3):165-72. PubMed ID: 16977795
[TBL] [Abstract][Full Text] [Related]
11. [Clinicopathological and biological features of breast cancer in young females and their relationship with prognosis].
Meng J; Lang RG; Fan Y; Fu L
Zhonghua Zhong Liu Za Zhi; 2007 Apr; 29(4):284-8. PubMed ID: 17760256
[TBL] [Abstract][Full Text] [Related]
12. REG1A expression is an independent factor predictive of poor prognosis in patients with breast cancer.
Sasaki Y; Minamiya Y; Takahashi N; Nakagawa T; Katayose Y; Ito A; Saito H; Motoyama S; Ogawa J
Ann Surg Oncol; 2008 Nov; 15(11):3244-51. PubMed ID: 18781363
[TBL] [Abstract][Full Text] [Related]
13. [Relationship of oncogene C-erbB2 expression to ER, PR and PS2 in breast cancer and its prognostic significance].
Yang JQ; Chen L; Xing TY
Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 May; 35(3):334-6, 357. PubMed ID: 15181828
[TBL] [Abstract][Full Text] [Related]
14. Expression of c-erbB-2 in node negative breast cancer does not correlate with estrogen receptor status, predictors of hormone responsiveness, or PCNA expression.
Kolár Z; Murray PG; Zapletalová J
Neoplasma; 2002; 49(2):110-3. PubMed ID: 12088102
[TBL] [Abstract][Full Text] [Related]
15. Bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor-negative breast carcinomas.
Wei B; Wang J; Bourne P; Yang Q; Hicks D; Bu H; Tang P
Hum Pathol; 2008 Dec; 39(12):1809-15. PubMed ID: 18715613
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
Høgdall EV; Christensen L; Høgdall CK; Blaakaer J; Gayther S; Jacobs IJ; Christensen IJ; Kjaer SK
Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific antigen in breast disease.
Poh BH; Jayaram G; Sthaneshwar P; Yip CH
Malays J Pathol; 2008 Jun; 30(1):43-51. PubMed ID: 19108411
[TBL] [Abstract][Full Text] [Related]
18. Comparison of HER-2/neu, ER and PCNA expression in premenopausal and postmenopausal patients with breast carcinoma.
Zheng W; Zheng J; Ma L; Meng F; Huang L; Ma D
APMIS; 2005 Mar; 113(3):175-81. PubMed ID: 15799760
[TBL] [Abstract][Full Text] [Related]
19. Immunocytochemical detection of prostate specific antigen expression in human breast carcinoma cells.
Bodey B; Bodey B; Kaiser HE
Anticancer Res; 1997; 17(4A):2577-81. PubMed ID: 9252683
[TBL] [Abstract][Full Text] [Related]
20. The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome in 'pure' ductal carcinoma in situ of the breast.
de Roos MA; van der Vegt B; Peterse JL; Patriarca C; de Vries J; de Bock GH; Wesseling J
Histopathology; 2007 Aug; 51(2):227-38. PubMed ID: 17650217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
